Literature DB >> 2940951

Cromolyn inhibition of mediator release in mast cells derived from mouse bone marrow.

D L Marquardt, L L Walker, S I Wasserman.   

Abstract

Mast cells derived from mouse bone marrow fail to demonstrate a disodium-cromoglycate-induced inhibition of mediator release when the cromolyn is added simultaneously with a secretagogue. To investigate the long-term effects of cromolyn exposure, cells from BALB/C femoral bone marrow stimulated with IL-3 were cultured in the presence of 1 to 100 microM cromolyn and demonstrated a similar viability and ability to proliferate as cells cultured in medium alone. Those cultured in cromolyn exhibited a significantly decreased A23187- or antigen-induced release of beta-hexosaminidase (4.3 +/- 0.7% versus 9.2 +/- 1.0%, p less than 0.01) compared with control cells. The adenosine-induced potentiation of mediator release was diminished to a comparable degree after cromolyn exposure in culture. This inhibition was dose-dependent between 1 and 100 microM cromolyn, evident by 5 days, reversible in 6 more days, and applied to immunoreactive leukotriene C4 generation as well. Bone marrow mast cells respond to chronic cromolyn exposure with a global inhibition of mediator release, but the basis for this response is unknown.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2940951     DOI: 10.1164/arrd.1986.133.6.1105

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  3 in total

1.  Evidence questioning cromolyn's effectiveness and selectivity as a 'mast cell stabilizer' in mice.

Authors:  Tatsuya Oka; Janet Kalesnikoff; Philipp Starkl; Mindy Tsai; Stephen J Galli
Journal:  Lab Invest       Date:  2012-08-20       Impact factor: 5.662

2.  Mucosal damage during intestinal anaphylaxis in the rat. Effect of betamethasone and disodium cromoglycate.

Authors:  R D'Incà; R H Hunt; M H Perdue
Journal:  Dig Dis Sci       Date:  1992-11       Impact factor: 3.199

3.  Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway.

Authors:  Arielle L Heeke; Joanne Xiu; Andrew Elliott; W Michael Korn; Filipa Lynce; Paula R Pohlmann; Claudine Isaacs; Sandra M Swain; Gregory Vidal; Lee S Schwartzberg; Antoinette R Tan
Journal:  Breast Cancer Res Treat       Date:  2020-08-10       Impact factor: 4.872

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.